BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 24469053)

  • 21. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma.
    Costa BM; Smith JS; Chen Y; Chen J; Phillips HS; Aldape KD; Zardo G; Nigro J; James CD; Fridlyand J; Reis RM; Costello JF
    Cancer Res; 2010 Jan; 70(2):453-62. PubMed ID: 20068170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.
    Bobustuc GC; Baker CH; Limaye A; Jenkins WD; Pearl G; Avgeropoulos NG; Konduri SD
    Neuro Oncol; 2010 Sep; 12(9):917-27. PubMed ID: 20525765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TRIM24 is upregulated in human gastric cancer and promotes gastric cancer cell growth and chemoresistance.
    Miao ZF; Wang ZN; Zhao TT; Xu YY; Wu JH; Liu XY; Xu H; You Y; Xu HM
    Virchows Arch; 2015 May; 466(5):525-32. PubMed ID: 25724180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
    Das A; Henderson FC; Alshareef M; Porto GBF; Kanginakudru I; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
    Clin Transl Oncol; 2021 Mar; 23(3):612-619. PubMed ID: 32710211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of TRIM24 by miR-511 modulates cell proliferation in gastric cancer.
    Fang Z; Zhang L; Liao Q; Wang Y; Yu F; Feng M; Xiang X; Xiong J
    J Exp Clin Cancer Res; 2017 Jan; 36(1):17. PubMed ID: 28114950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
    Moen EL; Stark AL; Zhang W; Dolan ME; Godley LA
    Mol Cancer Ther; 2014 May; 13(5):1334-44. PubMed ID: 24568970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas.
    Abe H; Natsumeda M; Kanemaru Y; Watanabe J; Tsukamoto Y; Okada M; Yoshimura J; Oishi M; Fujii Y
    Neurol Med Chir (Tokyo); 2018 Jul; 58(7):290-295. PubMed ID: 29848907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
    He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
    Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
    Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y
    Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glioblastoma Recurrence and the Role of O
    Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J
    JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
    Nie E; Jin X; Wu W; Yu T; Zhou X; Shi Z; Zhang J; Liu N; You Y
    J Neurooncol; 2017 May; 133(1):59-68. PubMed ID: 28425046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A
    J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
    Yang B; Ma YB; Chu SH
    Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MGMT Status as a Clinical Biomarker in Glioblastoma.
    Butler M; Pongor L; Su YT; Xi L; Raffeld M; Quezado M; Trepel J; Aldape K; Pommier Y; Wu J
    Trends Cancer; 2020 May; 6(5):380-391. PubMed ID: 32348734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
    BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.
    Grogan PT; Sarkaria JN; Timmermann BN; Cohen MS
    Invest New Drugs; 2014 Aug; 32(4):604-17. PubMed ID: 24718901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
    Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
    Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.